DOV 51892

**DOV 51892** is a novel anxioselective compound that acts as a **positive allosteric modulator** at the benzodiazepine binding site of **GABA_A receptors**. It exhibits higher efficacy than diazepam at **α1-containing GABA_A receptors** while demonstrating a non-sedative anxiolytic profile, lacking typical side effects like sedation, myorelaxation, or ataxia observed at behaviorally active doses in preclinical tests such as rotarod and grip strength assays. Developed by **DOV Pharmaceutical** for **anxiety disorders** including **panic disorder**, it belongs to a class of GABAkines designed for selective anxiolytic activity, with preclinical data supporting enhanced punished responding without motor impairment.[1][3][7][8][9]

Other names

7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl